#161964

VCaP 15 [ENZA F] CRPC Cell line

Cat. #161964

VCaP 15 [ENZA F] CRPC Cell line

Cat. #: 161964

Organism: Human

Tissue: Prostate

Disease: Cancer

Model: Tumour Cell Line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Wytske van Weerden

Institute: Erasmus University Medical Centre

Primary Citation: Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769712

Tool Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: VCaP 15 [ENZA F] CRPC Cell line
  • Parental cell: VCaP
  • Organism: Human
  • Tissue: Prostate
  • Disease: Cancer
  • Model: Tumour Cell Line
  • Model description: CRPC model
  • Receptors of note: Androgen receptor
  • Description: CRPC VCaP cell lines (15 sublines made resistant to common antiandrogens through long-term passaging) - Enzalutamide F. VCaP Enzalutamide cells were generated by long-term culturing of VCaP cells in androgen depleted media with Enzalutamide, an AR antagonist. These cell lines can be used to study the role of AR signalling and mechanisms of resistance to androgen deprivation therapy and AR targeting agents in CRPC. This cell line is subclone F.
  • Application: Tumour Modelling

Applications

  • Application: Tumour Modelling

Handling

  • Growth medium: RPMI1640 + 10% DCC-FCS + 1 uM ENZ
  • Storage conditions: liquid N2
  • Cultured in antibiotics: 1% Penicillin/Streptomycin

References

  • Moll JM et al. 2022. Front. Oncol. Jun 13,12:877613. PMID: 35769727